<table>
<thead>
<tr>
<th>項目</th>
<th>内容</th>
</tr>
</thead>
<tbody>
<tr>
<td>キーワード</td>
<td>金沢大学学術情報リポジトリ 金沢大学 Kanazawa University Repository for Academic resources</td>
</tr>
</tbody>
</table>

KURAに登録されているコンテンツの著作権は、執筆者、出版社（学協会）などが有します。
KURAに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。
著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。
GABAergic neurons in the preoptic area send direct inhibitory projections to orexin neurons

Yuki C. Saito1, Natsuko Tsujino1, Emi Hasegawa1, Kaori Akashi2, Manabu Abe2, Michihiro Mieda1, Kenji Sakimura2 and Takeshi Sakurai1*

1 Department of Molecular Neuroscience and Integrative Physiology, Faculty of Medicine, Kanazawa University, Kanazawa, Japan
2 Department of Cellular Neurobiology, Brain Research Institute, Niigata University, Niigata, Japan

*Correspondence:
Takeshi Sakurai, Department of Molecular Neuroscience and Integrative Physiology, Faculty of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan
e-mail: takeshi.sakurai@gmail.com

INTRODUCTION

The preoptic area (POA) of the hypothalamus has been implicated in a variety of physiological functions, including the regulation of sleep/wakefulness states (Boulant, 1981; McGinty et al., 2001). Especially, this region is thought to play an important role in the initiation and maintenance of sleep. Initially, electrical or chemical stimulation of the lateral POA in animals was shown to promote EEG slow-wave activity and sleep onset (Sterman and Clemente, 1962; Benedek et al., 1982; Ticho and Radulovacki, 1991; Mendelson and Martin, 1992). Consistently, lesions in the POA have been shown to result in profound and persistent sleep loss (John and Kumar, 1998; Lu et al., 2000). However, these studies are not genetically targeted to specific neuron types, and so the cells that are responsible remain to be clarified. In this study, we focused on the GABAergic neurons, as some of them have been shown to provide inputs in particular to the arousal system. We examined the role of the projection from GABAergic neurons in the POA to the orexin neurons in the LHA in inhibiting the latter cells, and the effect of activating this pathway on sleep.

Extracellular recording studies have identified sleep-active neurons in a region extending from the medial through the lateral POA (Kaitin, 1984; Koyama and Hayaishi, 1994), while it was reported that neurons in the rat ventrolateral preoptic area (VLPO) and median preoptic nucleus (MnPN) exhibited Fos expression following consolidated sleep (Gong et al., 2000). The POA was shown to send GABAergic inhibitory projections to monoaminergic regions, including the locus coeruleus (LC), dorsal raphe nucleus (DRN), and tuberomammillary nucleus (TMN) (Sherin et al., 1996, 1998; Steininger et al., 2001; Uschakov et al., 2007). Consistently, firing patterns of monoaminergic neurons in these nuclei across the sleep-waking cycle are the reciprocal of those observed in POA sleep-active neurons. They fire at a rapid rate during wakefulness, slow down during non-rapid eye movement (NREM) sleep, and cease firing during rapid eye movement (REM) sleep (Saper et al., 2001). Electrophysiological studies suggested that VLPO neurons are inhibited by noradrenaline and serotonin (Gallopin et al., 2000), suggesting mutually inhibitory interactions between VLPO and the monoaminergic arousal systems (Saper et al., 2001).

Monoaminergic arousal systems are also thought to be regulated by orexin neuropeptides, which are thought to be a critical regulator of sleep/wake states (Sakurai, 2007). Orexin deficiency causes the sleep disorder narcolepsy in humans and animals (Chemelli et al., 1999; Lin et al., 1999; Peyron et al., 2000;...
Thannickal et al., 2000; Hara et al., 2001). Orexin-producing neurons (orexin neurons) in the lateral hypothalamic area (LHA) send dense axonal projections to monoaminergic neurons in the brain stem/hypothalamic regions. Recent studies have suggested the POA also sends projections to orexin neurons in the LHA (Sakurai et al., 2005; Yoshida et al., 2006). However, how the endogenous firing of POA sleep-active neurons affects the activity of orexin neurons has been unknown. Functional studies of this issue are important, because both POA sleep active neurons and orexin neurons play highly important roles in the physiological regulation of sleep.

To examine the electrophysiological impact of activity of endogenous POA neurons, we first confirmed that selective pharmacogenetic stimulation of GABAergic neurons in the POA, using the Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technology, leads to an increase of NREM sleep (Armbruster et al., 2007). We also used channelrhodopsin-2 (ChR2) as an anterograde tracer as well as an optogenetic tool (Bernstein et al., 2012; Yizhar et al., 2011) for selective optical excitation of GABAergic POA neurons and their axons. We examined the axonal projections of ChR2-eYFP-positive fibers and confirmed that POA GABAergic neurons send abundant projections to arousal-related regions, including the LC, DR, TMN, and laterodorsal/pedunculopontine tegmental nuclei (LDT/PPT). Dense projections were also found in the LHA, and these GABAergic fibers made appositions to orexin neurons. We then explored the effects of fast and selective optogenetic stimulation of GABAergic neurons in the POA, combining whole-cell patch-clamp recordings from orexin neurons and identifying of orexin neurons (Figure 4A). Male mice were anesthetized with isoflurane and placed in a stereotaxic frame (David Kopf Instruments). For injection into the POA, two holes were drilled into the skull of Gad67-Cre mice (12–15 weeks of age, weight 25–30 g), at sites +0.3 mm anterior, ±0.65 mm lateral, and −5.72 mm ventral to the bregma under deep anesthesia. For injection into the LHA, four holes were drilled into the skull of each mouse under anesthesia, at sites −1.4 mm posterior, ±0.9 mm lateral, and −5.5 mm ventral; and −1.8 mm posterior, ±0.9 mm lateral, and −5.7 mm ventral to the bregma (four injection sites per mouse).

A Hamilton needle syringe (33-gauge) was placed at each site, and 0.5 µl purified virus was delivered to each site over a 10-min period. After 5 min of rest, the needles were removed. The mice were sacrificed 14 days later, and slice preparations were analyzed by electrophysiological experiments and tissue samples by immunohistochemical staining.

**MATERIALS AND METHODS**

**ANIMALS**

All experimental procedures involving animals were approved by the Animal Experiment and Use Committee of Kanazawa University (AP-132649), and were thus in accordance with NIH guidelines. Gad67-Cre mice, in which the Cre gene was knocked-in in the Gad67 allele were previously described (Wu et al., 2011). The mice were bred with wild type C57BL/6J mice more than ten times and maintained.

**AAV PRODUCTION AND PURIFICATION**

We used AAV with the FLEX switch system (Atasoy et al., 2008) to specifically express HA-tagged hM3Dq or ChR2 fused with EYFP (ChR2-EYFP) only in Cre recombinase-expressing neurons. We applied this method to heterozygous Gad67-Cre mice in which the Cre recombinase gene is specifically expressed in GABAergic neurons (Wu et al., 2011).

pAAV-DIO-HAhM3Dq was provided by Dr. Brian Roth. pAAV-DIO-hChR2(H134R)-EYFP-WPRE-pA was provided by Dr. Karl Deisseroth of Stanford University (Kozorovitskiy et al., 2012). We constructed a plasmid, pAAV-horexin-tdTomato-WPRE-pA, as follows. A 1.3-kb fragment of the human prepro-orexin gene promoter, which has the ability to drive expression in orexin neurons specifically (Moriguchi et al., 2002), was amplified by PCR with a pair of primers 5′-CAGCGGTGCATGCTGTAATCCCGAGCTAC-3′ and 5′-TGTGACGGTCTGTCGGAGTGCCTG-3′. The PCR product was fully sequenced and digested by MluI and SalI, and ligated to MluI and SalI-digested pAAV-DIO-hChR2(H134R)-EYFP-WPRE-pA, yielding pAAV-horexin-hChR2(H134R)-EYFP-WPRE-pA. The tdTomato gene fragment from pdTomato (Clontech) was inserted into the EcoRI and Sal sites of pAAV-horexin-hChR2(H134R)-EYFP-WPRE-pA, yielding pAAV-horexin-tdTomato-WPRE-pA.

Viruses were produced using a triple-transfection, helper-free method using a modification of a published protocol (Auricchio et al., 2001; Sasaki et al., 2011). The final purified viruses were aliquoted and stored at −80°C. The titers of AAV-DIO-hChR2(H134R)-EYFP and AAV-orexin-tdTomato were 1.63 × 10^{12} and 1.03 × 10^{12} genome copies/ml, respectively.

**VIRUS INJECTION**

Adenoassociated-virus AAV-DIO-HAhM3D or AAV-DIO-hChR2(H134R)-EYFP was injected into the POA of Gad67-Cre mice (Wu et al., 2011). In *in vitro* electrophysiological experiments for recording orexin neurons, AAV-orexin-tdTomato was simultaneously injected into the LHA of these mice for identification of orexin neurons (Figure 4A). Male mice were anesthetized with isoflurane and placed in a stereotaxic frame (David Kopf Instruments). For injection into the POA, two holes were drilled into the skull of Gad67-Cre mice (12–15 weeks of age, weight 25–30 g), at sites +0.3 mm anterior, ±0.65 mm lateral, and −5.72 mm ventral to the bregma under deep anesthesia. For injection into the LHA, four holes were drilled into the skull of each mouse under anesthesia, at sites −1.4 mm posterior, ±0.9 mm lateral, and −5.5 mm ventral; and −1.8 mm posterior, ±0.9 mm lateral, and −5.7 mm ventral to the bregma (four injection sites per mouse).

Acute slices containing the LHA were prepared from the mice 14 days post-AAV injection, as described in our previous studies (Tsujino et al., 2005). The mice were decapitated under deep anesthesia. Brains were isolated in ice-cold cutting solution consisting of (mM): 280 sucrose, 2 KCl, 10 HEPES, 0.5 CaCl_{2}, 10 MgCl_{2}, 10 glucose, pH 7.4, bubbled with 100% O_{2}. Brains were cut coronally into 300-µm slices with a vibratome (VTA-1200S, Leica, Germany). Slices were transferred to an incubation chamber at room temperature filled with physiological solution containing (mM): 125 NaCl, 2.5 KCl, 1.25 NaH_{2}PO_{4}, 2.0 CaCl_{2}, 1.0 MgSO_{4}, 26 NaHCO_{3}, 11 glucose, pH 7.4, bubbled with 95% O_{2}/5% CO_{2}. After 1-h incubation in an incubation chamber, the slices were transferred to a recording chamber (RC-27L,
Warner Instrument Corp., CT, USA) at 32°C on a fluorescence microscope stage (BX51WI, Olympus, Tokyo, Japan). Neurons that showed tdTomato fluorescence were used for patch-clamp recordings. The fluorescence microscope was equipped with an infrared camera (C-3077, Hamamatsu Photonics, Hamamatsu, Japan) for infrared differential interference contrast (IR-DIC) imaging and a CCD camera (JK-TU53H, Olympus) for fluorescence imaging. Each image was displayed separately on a monitor.

Recordings were carried out with an Axopatch 200B amplifier (Axon Instruments, Foster City, CA) using a borosilicate pipette (GC150-10, Harvard Apparatus, Holliston, MA) prepared using a micropipette puller (P-97, Sutter Instruments, Pangbourne, UK) and filled with intracellular solution (4–10 MΩ), consisting of (mM): 125 K-gluconate, 5 KCl, 1 MgCl₂, 10 HEPES, 1.1 EGTA-Na₃, 5 MgATP, 0.5 Na₂GTP, pH 7.3 with KOH. Osmolarity of the solution was checked with a vapor pressure osmometer (model 5520, Wescor, Logan, UT). The osmolarity of the internal and external solutions was 280–290 and 320–330 mOsm/l, respectively. The liquid junction potential of the patch pipette and perfused extracellular solution was estimated to be −16.2 mV and was applied to the data. The recording pipette was under positive pressure while it was advanced toward individual cells in the slice. Tight seals of 0.5–1.0 GΩ were made by applying negative pressure. The membrane patch was then ruptured by suction. The series resistance during recording was 10–25 MΩ and was compensated. The reference electrode was an Ag-AgCl pellet immersed in bath solution. During recordings, cells were superfused with extracellular solution at a rate of 1.0–2.0 ml/min using a peristaltic pump (K.T. Lab, Japan).

Light activation was performed using an LED device (KSL-70; Rapp OptoElectronic, Hamburg, Germany) at a wavelength of 470 nm (maximum: 8 mW/mm²). Pulse was generated with SEN-3301 stimulator (Nihon Koden, Japan).

CLOZAPINE-N-OXIDE ADMINISTRATION

Clozapine N-oxide (CNO; C8382, Sigma-Aldrich) was dissolved in saline to a concentration of 0.5 mg/ml. Silicon tubes were implanted for remote CNO injection. The tip of a 30 cm-long silicon tube was inserted 1 cm into the peritoneal cavity and sutured to the abdominal wall. The other end of the silicon tube was placed outside the body through an incision in the neck, and all incisions were sutured. All animals were then housed individually for a recovery period of at least 7 days. CNO was administered to each mouse (0.3 ml/30 g body weight) through the silicon tube. Injections were done at 21:00 and at 13:00.

SLEEP RECORDINGS

An electrode for EEG and EMG recording was implanted in the skull of each mouse as described previously (Hara et al., 2001). The three arms of the electrode for EEG recording were placed around the right, 2 mm posterior and 2 mm to the right, and 2 mm posterior and 2 mm to the left of the bregma. Stainless steel wires for EMG recording were sutured to the muscle muscles of each mouse bilaterally, and each electrode was glued solidly to the skull. After the recovery period, animals were moved to a recording cage placed in an electrically shielded and sound attenuated room. A cable for signal output was connected to the implanted electrode and animals were allowed to move freely. Signals were amplified through an amplifier (AB-611J, Nihon Koden, Tokyo) and digitally recorded on a computer using EEG/EMG recording software (Vital recorder, Kissei Comtec). Animals were allowed at least 7 days to adapt to the recording conditions prior to any EEG/EMG recording session. Following the adaptation period, each animal was intraperitoneally administered both CNO and saline on separate experimental days with a 3-day interval. The order of injection was randomized. EEG/EMG data were evaluated and staged for 3 h after administration. Data acquired on the day of saline administration were used as control. We analyzed FFT spectra of NREM period in 1–2 h epoch of saline- or CNO-injected mice (N = 14). Power spectral analysis of EEG signals was performed using custom FFT software.

IMMUNOHISTOCHEMISTRY

To confirm GABAergic-specific expression of Cre recombinase activity in the POA of Gad67-Cre mice, we crossed them with Rosa26-tomato tracer mice (B6; 129S6-Gt(ROSA)26Sortm9(CAG-tomato)Hze/J, Jackson Laboratory #007905). Mice at 8 weeks of age were deeply anesthetized with sodium pentobarbital and then fixed by intracardiac perfusion with 4% paraformaldehyde. Then, the brain was post-fixed for 24 h in the same fixative and cryoprotected by immersion in 30% sucrose for 2 days. Cryostat sections (40-µm thick) of the brains were incubated for 1 h in 0.1 M phosphate buffer containing 1% bovine serum albumin and 0.25% Triton-X-100, and incubated overnight at 4°C with rabbit anti-GAD65/67 antibody (Uchigashima et al., 2007) in the same solution. After three washes in the same solution, the sections were incubated with goat anti-rabbit IgG conjugated with Alexa 488 (Invitrogen, Carlsbad, CA) for 90 min at room temperature. After three washes in 0.1 M phosphate buffer, the sections were mounted on glass slides and cover-slipped. Slides were examined with a laser-confocal microscope (Olympus FV10i, Olympus, Japan).

To detect monoaminergic and cholinergic neurons, we used mouse anti-tyrosine hydroxylase (TPH) antibody (Sigma, T0648, 1:200), guinea pig anti-histidine decarboxylase (HDC) antibody (PROGEN Biotechnik GmbH, No.16046, 1:4000), rabbit anti-tyrosine hydroxylase (TH) antibody (Millipore, AB152, 1:2,000), and goat anti-choline acetyltransferase (ChAT) antibody (Millipore, Ab144D, 1:100). As a second antibody, Alexa Fluor 594-goat anti-mouse IgG (Molecular Probes, 1:800), Alexa Fluor 594-goat anti-guinea pig IgG (Molecular Probes, 1:800) were used.

To detect Fos immunoreactivity in orexin-expressing neurons, coronal sections were incubated overnight with rabbit anti-cFos antibody Ab-5 (Calbiochem, 1:10000) and guinea pig anti-orexin antibody in 0.1 M phosphate buffer containing 1% bovine serum albumin and 0.25% Triton X-100. The primary antibody was localized with the avidin-biotin system (Vector). Bound peroxidase was visualized by incubating sections with 0.01 M imidazole acetate buffer containing 0.05% hydrogen peroxide and 2.5% nickel ammonium sulfate, resulting in a black reaction product in the nuclei. The sections were then incubated with anti-guinea pig IgG and then with the avidin-biotin-peroxidase complex as described above. Nickel sulfate was omitted from the final reaction mix.
incubation, resulting in a golden brown reaction product in the cytoplasm. The numbers of cFos-positive and -negative orexin-containing neurons were counted in coronal sections throughout the hypothalamic region by a single examiner who was blinded to the treatment conditions, using a Keyence BZ-9000 microscope (Keyence, Japan). Cells were counted on both sides of the brain in consecutive 40-µm sections. Orexin neuron activity was scored as the percentage of double-labeled cells per animal.

**In situ HYBRIDIZATION**

Double in situ hybridization was performed according to procedures previously described (Mieda et al., 2006). For double in situ hybridization, each combination of two antisense riboprobes labeled with either fluorescein-UTP (Gad1) or digoxigenin-UTP (GFP) was hybridized to sections simultaneously. Following the chromogenic reaction of the first color (blue) obtained with antidigoxigenin-alkaline phosphatase (AP) Fab fragments, 5-bromo-4-chloro-3-indolyl phosphate (Roche) and nitroblue tetrazolium (Roche), sections were rinsed three times with TBS, treated twice with 0.1M glycine pH 2.2; 0.1% Tween 20 for 5 min, washed, and then incubated with anti-fluorescein-alkaline phosphatase (AP) Fab fragments. For the chromogenic reaction of the second color (orange), 5-bromo-4-chloro-3-indolyl phosphate (Roche) and 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyl-tetrazolium chloride (Roche) were used. Antisense riboprobes were synthesized from plasmids containing GFP and mouse Gad1 (NM_008077, nucleotides 281-821) cDNAs.

**STATISTICAL ANALYSIS**

Data were expressed as mean ± s.e.m. Two-way analysis of variance (ANOVA) followed by Bonferroni correction as a post-hoc test or Student’s t-test using IBM SPSS Statistics ver.19 was used for comparison among the various treatment groups. Differences were considered significant at \( p < 0.05 \).

**RESULTS**

**PHARMACOGENETIC SELECTIVE STIMULATION OF POA GABAergic NEURONS INCREASED NREM SLEEP**

Before examining the connectivity between POA GABAergic neurons and orexin neurons, we confirmed whether specific stimulation of GABAergic neurons in the POA affects sleep/wakefulness states in mice. We applied the DREADD technology (Arnimbruster et al., 2007; Sasaki et al., 2011), to pharmacogenetically manipulate the activity of POA GABAergic neurons. To express hM3Dq in GABAergic neurons in the POA, we injected AA-V-DIO-HAhM3Dq into the POA of Gad67-Cre mice, in which GABAergic neurons specifically express Cre recombinase (Wu et al., 2011). GABAergic specific expression of Cre recombinase in the POA of Gad67-Cre mice was confirmed by crossing them with ROSA26-tdTomato mice (containing tdTomato gene preceded by a transcriptional blocker flanked with lox-P sites) (Figure 1A). We confirmed virtually all tdTomato-expressing neurons were positive for Gad65/67 immunoreactivity (95.4%). After injection of AA-V-DIO-HAhM3Dq, we implanted thin silicone tubes into the peritoneal space of Gad67-Cre mice so that we could administer clozapine-N-oxide (CNO), the synthetic ligand for hM3Dq, with minimal disturbance. Fourteen days after virus injection, we administered CNO to mice.

Fourteen days after the virus injection, we administered CNO or saline intraperitoneally to Gad67-Cre mice expressing hM3Dq at 13:00 (light period) or 21:00 (dark period). The sleep/wakefulness states of these mice were monitored by simultaneous EEG/EMG recording. As a control, we treated the same mice with saline on separate experimental days. Each mouse was administered CNO or vehicle using a randomized crossover design at an interval of 3 days.

After the recording, mice were subjected to immunostaining with anti-HA antibody. We observed expression of HA-immunoreactivity in the POA region of most mice (Figure 1B). We injected the virus in 62 mice, and only used data obtained from 14 mice in which the existence of HA-positive cell bodies was limited within the POA. In many cases, we observed expression of HA-positive cells outside the POA, including the basal forebrain regions, such as the horizontal nucleus of the diagonal band. Therefore, we gathered data from 14 mice, in which HA-immunoreactivity was confined in the POA.

After the EEG/EMG recordings, we injected CNO \((n = 8)\) or saline \((n = 6)\) into Gad67-Cre mice expressing hM3Dq at 21:00, sacrificed and fixed them at 23:00. Hypothalamic slices of these mice were examined by double staining with anti-Fos and anti-Gad65/67 antibodies to assess the activity of POA neurons (Figure 1C).

We observed an approximately 2.5-fold increase in Fos-positive GABAergic neurons in the whole POA of the CNO-injected group as compared with the vehicle-injected group \((29.7 ± 3.7\% \text{ vs. } 76.6 ± 4.3\%), \ p < 0.001\) (Figure 1C). These observations demonstrate that the DREADD system used in this study appropriately stimulates the activity of POA neurons.

EEG/EMG analyses found that the percent of wakefulness during 3 h after CNO administration was significantly shorter \((128.3 ± 3.5\text{ min. vs. } 112.7 ± 4.1 \text{ min, } \ p = 0.006)\), while NREM time was longer in CNO-treated conditions than in saline-injected control conditions in the dark period \((49.9 ± 3.0\text{ min vs. } 65.1 ± 3.1 \text{ min, } \ p = 0.004)\) (Figure 2A). A significant increase of NREM sleep was also observed for 3 h after administration in the light period (13:00). We observed an increase in NREM episode duration when CNO was administered in the light period (Figure 2B). Although we also observed similar tendency when CNO was administered in the dark period, the difference was not statistically significant. The power density of EEG of each episode in the CNO-administered group in the dark period showed no difference from that in the vehicle-administered group (Figure 2C).

These results suggest that, consistent with previous non-specific electrical and chemical stimulation studies of the POA, specific stimulation of POA GABAergic neurons results in a decrease of wakefulness time, accompanied by increased NREM sleep time. We did not observe a significant difference in REM sleep time between the CNO-injected and control groups (Figure 2A).

We next examined the effect of stimulation of POA GABAergic neurons on orexin neuronal activity by Fos-immunostaining. After CNO or saline was injected at 21:00, the brains were fixed
Saito et al. POA neurons inhibit orexin neurons

FIGURE 1 | Selective pharmacogenetic stimulation of POA neurons. (A) Gad67-Cre mice were crossed with Rosa26-tdTomato reporter mice (see method) to confirm GABAergic neuron-specific expression of Cre recombinase. A representative image of the POA of the Gad67-Cre; Rosa26-tdTomato mice is shown (Bregma-0.1 mm). Left panels, upper, tdTomato fluorescence. Lower, same section stained with Gad65/67 antibody. Middle panel, merged image of rectangular region in the left panel. Right panel: High power view of rectangular region in central panel. Arrowheads show the colocalization of tdTomato fluorescence and Gad65/67 immunoreactivity. (B) Left, Virus injection sites are shown by dots. Injection site for right panel image is shown by a red dot. Right, Representative image of HA-like immunoreactivity observed in POA region of Gad67-Cre mice injected with AAV-DIO-HAhM3Dq to express hM3Dq fused with HA tag. (C) Activation of POA neurons in Gad67-Cre mice expressing hM3Dq by CNO. Left panels, upper, representative images of double-immunostaining with anti-Fos and anti-Gad65/67 in the POA region after administration of saline (left) or CNO (right) at 21:00. The brain was fixed at 23:00. Left panels, lower, high power view of the rectangular regions shown in upper panels. Arrowheads show the colocalization of Fos (nuclei) and Gad65/67 (cytoplasm). Right panel, Number of fos-immunoreactive GABAergic neurons in POA after treatment with saline or CNO (N = 4 and 4, respectively).

at 23:00, and subjected to double staining with anti-orexin and anti-Fos antibody. We observed decrease in number of double positive cells (45.1 ± 6.5% vs. 27.3 ± 5.3%) (Figure 2D), although it was unknown whether the inhibition was directly mediated by POA GABAergic neurons or rather resulted from increased amount of sleep, because orexin neuronal activity was shown to correlate with the amount of wakefulness (Estabrooke et al., 2001).

POA GABAergic NEURONS SEND INNERVATIONS TO REGIONS IMPLICATED IN THE REGULATION OF SLEEP/WAKEFULNESS STATES

We next examined whether POA GABAergic neurons directly innervate orexin neurons. We injected AAV-DIO-hChR2(H134R)-EYFP into the POA of Gad67-Cre mice, because ChR2 works well as an anterograde tracer (Harris et al., 2012). Because ChR2-eYFP is distributed in axons and dendrites, it is difficult to observe cell bodies of neurons that express
FIGURE 2 | Specific pharmacogenetic stimulation of GABAergic neurons in the POA increased NREM sleep amount. (A) Total time of wakefulness (WAKE), NREM sleep and REM sleep for 3 h after CNO (or saline) administration at 21:00 (upper panels, Saline n = 14, CNO n = 13) and at 13:00 (lower panels, Saline n = 7, CNO n = 7). (B) Episode duration of WAKE, NREM sleep, and REM sleep for 3 h after CNO (or saline) administration at 21:00 (upper panels, Saline n = 14, CNO n = 13) and at 13:00 (lower panels, Saline n = 7, CNO n = 7). (C) EEG power density of WAKE, NREM sleep and REM sleep in 1–2 h time window after the administration of CNO or saline at 21:00 (Saline n = 14, CNO n = 13). EEG power density is shown as the mean percentage of total EEG power ± s.e.m. (D) Representative images of fos expression in orexin neurons, as shown by double staining of the LHA of Gad67-Cre mice 2 h after injection of saline (n = 5) or CNO (n = 8) at 21:00. Scale bars, 50µm. Right panel, ratio of Fos-positive orexin neurons after injections of saline or CNO. Arrowheads show colocalization of Fos (nuclei) and orexin (cytoplasm).
ChR2-eYFP, we examined the expression pattern of ChR2-eYFP mRNA in the POA by double label in situ hybridization to detect the original cell bodies that expressed ChR2-eYFP mRNA and Gad67 mRNA (Figure 3A). ChR2-eYFP mRNA-expressing cells were widely spread within the POA. Almost all these ChR2-eYFP mRNA-positive neurons also expressed Gad67 mRNA. We injected the virus into 27 mice, and selected four mice in which Gad67 mRNA expression was confirmed to be restricted within the POA.

Following the specific expression of ChR2 in GABAergic neurons in the POA of Gad67-Cre mice, we observed a network of ChR2-containing axons in the brain by immunostaining the YFP-positive fibers (Figure 3B, Table 1). We found abundant ChR2-eYFP-positive fibers in many of known arousal-related

![Image](image-url)
Table 1 | Projection sites of POA GABAergic neurons.

<table>
<thead>
<tr>
<th>Cell group</th>
<th>Relative density</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. FOREBRAIN</td>
<td></td>
</tr>
<tr>
<td>A. Isocortex</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>±</td>
</tr>
<tr>
<td>II</td>
<td>±</td>
</tr>
<tr>
<td>III</td>
<td>±</td>
</tr>
<tr>
<td>IV</td>
<td>±</td>
</tr>
<tr>
<td>V</td>
<td>±</td>
</tr>
<tr>
<td>VI</td>
<td>±</td>
</tr>
<tr>
<td>Claustrum</td>
<td>++</td>
</tr>
<tr>
<td>Endopiriform nucleus</td>
<td>++</td>
</tr>
<tr>
<td>B. Hippocampal formation</td>
<td></td>
</tr>
<tr>
<td>1. Entorhinal area</td>
<td>+</td>
</tr>
<tr>
<td>2. Subculum</td>
<td>+</td>
</tr>
<tr>
<td>3. CA1</td>
<td>+</td>
</tr>
<tr>
<td>4. CA2</td>
<td>+</td>
</tr>
<tr>
<td>5. CA3</td>
<td>+</td>
</tr>
<tr>
<td>6. Dentate</td>
<td>±</td>
</tr>
<tr>
<td>7. Induseum griseum</td>
<td>–</td>
</tr>
<tr>
<td>C. Amygdala</td>
<td></td>
</tr>
<tr>
<td>1. Medial nucleus</td>
<td>++</td>
</tr>
<tr>
<td>2. Amygdalohippocampal area</td>
<td>–</td>
</tr>
<tr>
<td>3. N. lat. Olfactory tract</td>
<td>–</td>
</tr>
<tr>
<td>4. Anterior amygdaloid area</td>
<td>–</td>
</tr>
<tr>
<td>5. Central nucleus</td>
<td>–</td>
</tr>
<tr>
<td>6. Lateral nucleus</td>
<td>–</td>
</tr>
<tr>
<td>7. Basolateral nucleus</td>
<td>+</td>
</tr>
<tr>
<td>8. Basomedial nucleus</td>
<td>+</td>
</tr>
<tr>
<td>9. Intericalated nuclei</td>
<td>+</td>
</tr>
<tr>
<td>10. Cortical nucleus</td>
<td>+</td>
</tr>
<tr>
<td>D. Septum</td>
<td></td>
</tr>
<tr>
<td>1. Lateral nucleus</td>
<td>+++</td>
</tr>
<tr>
<td>Dorsal part</td>
<td>+++</td>
</tr>
<tr>
<td>Intermediate part</td>
<td>+++</td>
</tr>
<tr>
<td>Ventral part</td>
<td>+++</td>
</tr>
<tr>
<td>2. Medial nucleus</td>
<td>+++</td>
</tr>
<tr>
<td>3. Bed n. stria terminalis</td>
<td>+++</td>
</tr>
<tr>
<td>Rostromedial resion</td>
<td>+++</td>
</tr>
<tr>
<td>Rostrolateral resion</td>
<td>+++</td>
</tr>
<tr>
<td>Posterodorsal resion</td>
<td>+++</td>
</tr>
<tr>
<td>Posteroventral resion</td>
<td>+++</td>
</tr>
<tr>
<td>4. Septofimbrial nucleus</td>
<td>+++</td>
</tr>
<tr>
<td>5. Subfornical organ</td>
<td>+++</td>
</tr>
<tr>
<td>6. Bed n. anterior commissure</td>
<td>+++</td>
</tr>
<tr>
<td>E. Basal ganglia</td>
<td></td>
</tr>
<tr>
<td>1. Caudato putamen</td>
<td>–</td>
</tr>
<tr>
<td>2. Glabus pallidus</td>
<td>–</td>
</tr>
<tr>
<td>3. Substantia nigra, Compact part</td>
<td>+++</td>
</tr>
<tr>
<td>4. Substancia nigra, reticular part</td>
<td>–</td>
</tr>
<tr>
<td>5. Subthalamic nucleus</td>
<td>++</td>
</tr>
<tr>
<td>F. Thalamus</td>
<td></td>
</tr>
<tr>
<td>1. Medial habenula</td>
<td>+++</td>
</tr>
<tr>
<td>2. Lateral habenula</td>
<td>+++</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1 | Continued

<table>
<thead>
<tr>
<th>Cell group</th>
<th>Relative density</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lateral preoptic area</td>
<td>+++</td>
</tr>
<tr>
<td>Lateral hypothalamic area</td>
<td>+++</td>
</tr>
<tr>
<td>Posterior hypothalamic area</td>
<td>+++</td>
</tr>
</tbody>
</table>

#### II. BRAIN STEM

**A. Sensory**

1. **Visual**
   - Superior colliculus: –
   - Parabigeminal n.: –
   - Pretectal resion: –
   - Olivary n.: –
   - N. optic tract: –
   - Anterior n.: –
   - Posterior n.: –
   - Medial prepectal area: –
   - N. posterior commissure: –

2. **Somatosensory**
   - Mesencephalic n. (5): +
   - Principal sensory, n. (5): –
   - Spinal n.: –
   - Gracile n., dorsal: –

3. **Auditory**
   - Cochlear nuclei: ±
   - Dorsal: –
   - Ventral: –
   - N. trapezoid body: ±
   - Superior olive: +
   - N. lateral lemniscus: –
   - Inferior colliculus: –
   - Exterminal: –
   - Dorsal: –
   - Central: –
   - N. brachium int. Coll.: –

4. **Vestibular**
   - –

5. **Visceral**
   - N. solitary tract: –
   - Area postrema: –
   - Parabranchial n.: –
   - Lateral: +
   - Medial: +

#### B. Motor

1. **Eye**
   - Oculomotor(3): +
   - Edinger-westphal nucleus: + +
   - Trochlear(4): +
   - Abducens(6): –

2. **Jaw**
   - Motor n. (5): –

3. **Face**
   - Facial n. (7): ±

4. **Pharynx/larynx**

#### C. Reticular core (including central gray and raphe)

1. **Periaqueductal gray-assoc. w/PAG**
   - Interstitial n. of cajal: –
   - Dorsal tegmental n.: –

2. **Raphe**
   - Interfascicular n.: + + +
   - Rostral linear n.: + + +
   - Dorsal raphe: + + +
   - Median raphe: + + +
   - N. raphe pontis: + + +
   - N. raphe magnus: + + +
   - N. raphe pallidus: + + +

3. **Interpeduncular n.**
   - Rostral subnucleus: ±
   - Apical subnucleus: ±
   - Dorsomedial subnucleus: –
   - Lateral subnucleus: ±
   - Intermediate subnucleus: +
   - Central subnucleus: +

4. **Reticular formation**
   - Central teg. field: +
   - Peripeduncular n.: –
   - Pedunculopontine n.: ++
   - Cuneiform n.: ++
   - Pontine reticular: +
   - Parvocellular ret. Firld: +
   - Gigantocellular ret.: +
   - Lat. paragigantocellular: +
   - Intermediate ret. field: –
   - Paramedian reticular n.: –

#### D. Pre- and postzerebellar

1. **Pontine gray**
2. **Tegmental reticular n.**
3. **Lateral reticular n.**

4. **Red nucleus**
5. **N.Roller**
6. **Prepositus hypoglossal nucleus**

#### III. CEREBELLUM

1. **Flocculus**
2. **Other parts**

We attempt to grade the density of fiber-like structures in the sections into five categories according to Nambu et al. (1999); dense (+ + +); moderately dense (+ +); sparse (+); very sparse (–).
regions in the hypothalamus and brain stem, including the LHA, ventral tegmental area (VTA), substantia nigra pars compacta (SNCs), TMN, LC, and LDT (Figure 3B). The projecting fibers seemed to avoid the main part of the dorsal raphe (DR), and density of the fibers in the PPT was sparser than other arousal-related regions, although we found considerable numbers of YFP-positive fibers in these regions (Figure 3C). Double staining studies suggested that these fibers made apposition to LC noradrenergic neurons, PPT cholinergic neurons, DR serotonergic neurons and TMN histaminergic neurons (Figure 3C). When we infected AAV-DIO-hChR2(H134R)-EYFP into the POA unilaterally, most of (>95%) the axonal projections were found in the ipsilateral side (not shown).

We found prominent projections to the LHA (Figures 3B,C), in which orexin neurons are localized. Double staining of LHA slices with anti-GFP and anti-orexin antibodies showed that most orexin neurons in the LHA were densely surrounded by rich ChR2-EYFP fibers (Figure 3C). This suggests that POA GABAergic neurons send innervations to orexin neurons in the LHA.

**DETECTING SPIKE-MEDIATED GABA RELEASE FROM AXONS OF POA NEURONS ONTO OREXIN NEURONS**

To test if stimulation of these axons modulates activity of orexin neurons, we performed whole-cell patch-clamp recordings from orexin neurons during optical stimulation of ChR2-EYFP-containing axons. To make identification of orexin neurons easy, we expressed tdTomato specifically in orexin neurons by AAV-mediated gene transfer (AAV-horexin-tdTomato). We used the human prepro-orexin promoter (Sakurai et al., 1999) to express tdTomato specifically in orexin neurons (Figure 4A). Immunolabeling confirmed that virtually all (>97%, n = 3) tdTomato-expressing neurons also contained detectable orexin-like immunoreactivity, suggesting highly specific expression of tdTomato in orexin neurons after injection of AAV (Figure 4B), although there were many orexin neurons that were negative for tdTomato fluorescence, suggesting incomplete penetrance of the virus-mediated expression.

To examine the connectivity between POA GABAergic neurons and orexin neurons, we simultaneously injected AAV-DIO-hChR2(H134R)-EYFP into the POA and AAV-horexin-tdTomato in the LHA of Gad67-Cre mice. 14 days after the injection, we prepared acute LHA slices and made patch clamp recordings from red fluoresced cell. We then stimulated axons with light emitting diode (LED) light of 470 nm in a 90-µm diameter window surrounding recorded orexin neurons. When orexin neurons were recorded under current-clamp with zero holding current, the light flashes slowed firing rate (Figure 4C). After recording for several minutes without stimuli, we applied 20-ms light stimuli (10 Hz). Since a previous study suggested the firing rates of sleep-active neurons in the POA ranged between about 5 and 20 Hz (Takahashi et al., 2009), we tried stimulation frequencies of 6, 10, and 20 Hz, and found that frequencies above 20 Hz evoked strong inhibition, but this lasted a very short time (for only about 2s). Because 10Hz stimulation caused strong and long-lasting inhibition of orexin neurons (data not shown), we used 10 Hz stimulation throughout this study. The inhibition of orexin neuron firing was completely abolished by a specific GABAA antagonist, bicuculline (Figure 4C).

Optical stimulation of ChR2-axons located near orexin neurons produced fast inhibitory post-synaptic currents (IPSCs) in these cells (Figure 4D). Orexin neurons from slices prepared from mice without ChR2 expression did not show any membrane responses to the same light flashes (n = 10, data not shown), confirming that without ChR2, our optical stimulation does not affect synaptic input to orexin neurons. In ChR2-expressing slices, the delay between flash onset and post-synaptic response was 3.4 ± 1.3 ms (Figure 4E). This short delay suggests that it is likely that GABAergic fibers extending from the POA directly inhibit orexin neurons. These observations show that GABAergic axons originating from POA neurons modulate orexin neurons via GABAA receptor-mediated synaptic transmission.

**DISCUSSION**

Extracellular recording studies have demonstrated cells in the POA that display elevated firing rates during sleep with attenuated firing during wakefulness (Findlay and Hayward, 1969; Kaitin, 1984). The discharge rate of these “sleep-active” neurons increased several seconds prior to NREM sleep onset as defined by EEG changes. These observations suggest that the POA plays an important role in the initiation and maintenance of sleep. Approximately 80% of sleep-active neurons in the VLPO also contain the neuropeptide galanin, which is highly colocalized with GABA in VLPO neurons (Sherin et al., 1998; Gaus et al., 2002). The number of Fos and GAD-double positive neurons in both the MnPN and the VLPO was shown to be positively correlated with the amount of preceding sleep (Gong et al., 2004).

These POA sleep-regulatory neurons were shown to be activated by adenosine through both direct and indirect actions. Adenosine caused A1 receptor-mediated suppression of spontaneous IPSPs in rat VLPO neurons recorded in vitro (Chamberlin et al., 2003). Moreover, an adenosine A2A receptor agonist evoked direct excitatory effects on a subset of rat VLPO neurons (Gallopin et al., 2005). Furthermore, perfusion of an A2A agonist into the POA in rats promoted sleep (Satoh et al., 1999). These mechanisms have been thought to play an important role in homeostatic regulation of sleep through actions of adenosine.

A recent extracellular recording study suggested widespread distribution of sleep-active neurons within the whole POA (Takahashi et al., 2009), so it is necessary to genetically target the cell types being manipulated. In this study, we expressed hM3Dq or ChR2 broadly in GABAergic neurons in the POA. Firstly, we confirmed that specific stimulation of POA GABAergic neurons leads to an increase of NREM time (Figure 2). Sasaki et al. (2011) reported the same or even more NREM induction by hM4D-mediated inhibition of orexin neurons. This was unexpected, because the activation of POA GABA neurons should suppress more wake-active neurons widely throughout the brain. One possible reason why the effects were not so strong in this study is that we activated large numbers of GABAergic neurons in the POA. It is known that only limited number of GABAergic neurons in the POA would become active during sleep. However, in this study, larger numbers of the GABAergic neurons in the POA, including GABAergic interneurons, might be activated.
FIGURE 4 | Optogenetic stimulation of POA GABAergic axons rapidly decreases orexin neuron firing. (A) Strategy of this study. We simultaneously injected AAV-horexin-tdTomato into the LHA and AAV-DIO-hChR2(H134R)-eYFP into the POA. (B) Identification of orexin neurons in the LHA by expression of tdTomato in these neurons after injection of AAV-horexin-tdTomato. Left: Coronal section at bregma −2.1 mm showing distribution of orexin neurons stained by anti-orexin antiserum (green). Center: Cells with red fluorescence of tdTomato. Right: Merged image (C) Typical electrical current-clamp recording of orexin neuron. Left: Example of changes in firing of orexin neurons induced by optical stimulation in the absence (top trace) and presence (bottom trace) of bicuculline (20 µM). We observed similar responses in three out of eight cells. Right: Group data for response and recovery at 10 Hz stimulation, expressed as % change in firing before (B), during (S) and after (R) light stimulation. (D) Optogenetically induced IPSCs in orexin neurons with and without bicuculline (20 µM). Holding potential was −60 mV. Black bar indicates light stimulus (5 ms, 1 Hz). Individual responses without bicuculline are shown in gray, average without bicuculline is in black, and average with bicuculline is in red. (E) Times after light-on to IPSPs onset are plotted for individual stimulations.
Some population of GABAergic neurons might rather inhibit sleep-active neurons to counteract direct activation of these cells by CNO.

We also expressed ChR2-eYFP selectively in GABAergic neurons in the POA of Gad67-Cre mice. This allowed us to trace axonal fibers of these cells, and perform fast electrical control of action potential firing of these fibers with light (Petreanu et al., 2007). Firstly, we examined the pattern of axonal projections by staining eYFP with an anti-GFP antibody. This revealed that GABAergic neurons in the POA send projections to arousal-regulating regions in the brain stem, including the LC, DR, LDT/PPT, and TMN (Figures 3B,C, Table 1). Double immunofluorescence study further suggested that these axonal fibers make appositions to orexin neurons in the LHA as well as other arousal-related neurons including TH-positive, noradrenergic cells in the LC, serotonergic cells in the raphe nuclei, cholinergic neurons in the LDT, and histaminergic cells in the TMN (Figure 3C).

We next examined the effect of optogenetic stimulation of ChR2-positive fibers around orexin neurons in the LHA (Figure 4). In the stimulation paradigms used here, blockade of GABAA receptors completely abolished the post-synaptic effect of GABAergic axon stimulation, suggesting that release of other transmitters, such as galanin, was not sufficient to alter orexin neuron firing.

Previous studies as well as our present findings suggest that POA GABAergic neurons send rich innervations to multiple brain regions, including monoaminergic/cholinergic nuclei in the brain stem, which fire at a rapid rate during wakefulness, slow down during NREM sleep, and cease firing during REM sleep, and are implicated in maintenance of wakefulness (Figure 3B). This means it is difficult to speculate on the relative contribution of the inhibitory action on orexin neuronal activity in increasing NREM sleep time. However, because specific pharmacogenetic or optogenetic inhibition of orexin neurons was shown to increase NREM sleep (Sasaki et al., 2011; Tsunematsu et al., 2011), it is possible to speculate that POA GABAergic neuron-mediated NREM sleep promotion might be at least partly through the inhibition of orexin neurons. Further studies, including optogenetic/pharmacogenetic activation/inhibition of POA GABAergic neurons in vivo in orexin-deficient animals, will be required to address this.

ACKNOWLEDGMENTS

This study was supported by the Cabinet Office, the Government of Japan through its “Funding Program for Next Generation World-Leading Researchers.” The authors thank Dr. Wendy Gray for reading the manuscript. The authors thank Dr. Karl Deisseroth for providing pAAV-double-flaxed-hChR2(H134R)-EYFP-WPRE-pA, Dr. Brian L. Roth for pAAV-DIO-HahM3Dq and Dr. Masahiko Watanabe for providing anti-Gad65/67 antibody.

REFERENCES


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 06 August 2013; accepted: 13 November 2013; published online: 02 December 2013.


This article was submitted to the journal Frontiers in Neural Circuits. Copyright © 2013 Saito, Tsujino, Hasegawa, Akashi, Abe, Mieda, Sakamura and Sakurai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.